Celularity, Inc. (NASDAQ:CELU) Sees Significant Decrease in Short Interest

Celularity, Inc. (NASDAQ:CELU) was the recipient of a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 355,364 shares, a decline of 27.3% from the January 29th total of 488,580 shares. Approximately 1.5% of the company’s shares are short sold. Based on an average daily volume of 30,892 shares, the days-to-cover ratio is currently 11.5 days. Based on an average daily volume of 30,892 shares, the days-to-cover ratio is currently 11.5 days. Approximately 1.5% of the company’s shares are short sold.

Celularity Stock Performance

Celularity stock traded down $0.01 during midday trading on Monday, reaching $1.22. The stock had a trading volume of 7,275 shares, compared to its average volume of 34,387. The stock has a market capitalization of $35.18 million, a P/E ratio of -0.37 and a beta of 0.79. The firm’s fifty day simple moving average is $1.27 and its 200-day simple moving average is $1.88. Celularity has a 1-year low of $1.00 and a 1-year high of $4.35.

Institutional Trading of Celularity

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Perennial Investment Advisors LLC bought a new stake in Celularity during the third quarter worth $28,000. Acadian Asset Management LLC acquired a new position in shares of Celularity during the 1st quarter valued at $34,000. XTX Topco Ltd raised its stake in Celularity by 106.4% during the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock worth $42,000 after buying an additional 11,057 shares during the period. Bank of America Corp DE grew its holdings in shares of Celularity by 1,538.1% during the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after buying an additional 35,023 shares during the last quarter. Finally, HB Wealth Management LLC bought a new stake in shares of Celularity in the 3rd quarter worth $84,000. Institutional investors own 19.02% of the company’s stock.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.